AU2001275378A1 - Methods and compositions for inhibiting immunoglobulin-mediated reperfusion inj ury - Google Patents

Methods and compositions for inhibiting immunoglobulin-mediated reperfusion inj ury

Info

Publication number
AU2001275378A1
AU2001275378A1 AU2001275378A AU7537801A AU2001275378A1 AU 2001275378 A1 AU2001275378 A1 AU 2001275378A1 AU 2001275378 A AU2001275378 A AU 2001275378A AU 7537801 A AU7537801 A AU 7537801A AU 2001275378 A1 AU2001275378 A1 AU 2001275378A1
Authority
AU
Australia
Prior art keywords
methods
compositions
immunoglobulin
mediated reperfusion
inj ury
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001275378A
Inventor
Michael C. Carroll
Herbert B. Hechtman
Francis D. Moore Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immune Disease Institute Inc
Original Assignee
BLOOD RES CENTER
Immune Disease Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BLOOD RES CENTER, Immune Disease Institute Inc filed Critical BLOOD RES CENTER
Publication of AU2001275378A1 publication Critical patent/AU2001275378A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Methods and compositions for treating or preventing immunoglobulin-mediated reperfusion or ischemic injury, in a subject, are provided. Methods for identifying inhibitors of an interaction between a pathogenic immunoglobulin and an ischemic antigen or a component of the complement pathway are provided. Pathogenic immunoglobulins and mutated forms thereof are also disclosed.
AU2001275378A 2000-06-08 2001-06-08 Methods and compositions for inhibiting immunoglobulin-mediated reperfusion inj ury Abandoned AU2001275378A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21027200P 2000-06-08 2000-06-08
US60210272 2000-06-08
PCT/US2001/018510 WO2001093892A1 (en) 2000-06-08 2001-06-08 Methods and compositions for inhibiting immunoglobulin-mediated__reperfusion injury

Publications (1)

Publication Number Publication Date
AU2001275378A1 true AU2001275378A1 (en) 2001-12-17

Family

ID=22782260

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001275378A Abandoned AU2001275378A1 (en) 2000-06-08 2001-06-08 Methods and compositions for inhibiting immunoglobulin-mediated reperfusion inj ury

Country Status (9)

Country Link
EP (2) EP2251026A1 (en)
JP (1) JP2004502412A (en)
CN (1) CN1443074A (en)
AT (1) ATE459367T1 (en)
AU (1) AU2001275378A1 (en)
CA (1) CA2410458A1 (en)
DE (1) DE60141463D1 (en)
ES (1) ES2343351T3 (en)
WO (1) WO2001093892A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100136684A1 (en) * 2004-03-01 2010-06-03 Carroll Michael C Natural IgM Antibodies
WO2005085288A2 (en) 2004-03-01 2005-09-15 The Cbr Institute For Biomedical Research Natural igm antibodies and inhibitors thereof
AU2012200909B2 (en) * 2004-03-01 2013-10-03 Immune Disease Institute, Inc Natural lgM antibodies and inhibitors thereof
WO2009035055A1 (en) * 2007-09-14 2009-03-19 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Insulin-like growth factor-1 (igf-1) production promoter

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (en) 1984-08-15 1986-03-07 Res Dev Corp Of Japan Chimera monoclonal antibody and its preparation
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (en) 1984-12-04 1986-06-21 Teijin Ltd Expression of hybrid antibody gene
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
AU4308689A (en) 1988-09-02 1990-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
WO1991007087A1 (en) 1989-11-13 1991-05-30 Affymax Technologies N.V. Spatially-addressable immobilization of anti-ligands on surfaces
JP3068180B2 (en) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド Generation of heterologous antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ATE158021T1 (en) 1990-08-29 1997-09-15 Genpharm Int PRODUCTION AND USE OF NON-HUMAN TRANSGENT ANIMALS FOR THE PRODUCTION OF HETEROLOGUE ANTIBODIES
ATE352612T1 (en) 1990-08-29 2007-02-15 Pharming Intellectual Pty Bv HOMOLOGOUS RECOMBINATION IN MAMMAL CELLS
DK0564531T3 (en) 1990-12-03 1998-09-28 Genentech Inc Enrichment procedure for variant proteins with altered binding properties
EP0562025B1 (en) 1990-12-06 2001-02-07 Affymetrix, Inc. (a Delaware Corporation) Compounds and their use in a binary synthesis strategy
ATE363532T1 (en) 1991-03-01 2007-06-15 Dyax Corp METHOD FOR PRODUCING BINDING MINIPROTEINS
ES2315612T3 (en) 1991-04-10 2009-04-01 The Scripps Research Institute GENOTECAS OF HETERODYMERIC RECEPTORS USING PHAGEMIDS.
DE4122599C2 (en) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid for screening antibodies
ATE241426T1 (en) 1991-11-22 2003-06-15 Affymetrix Inc A Delaware Corp METHOD FOR PRODUCING POLYMER ARRAYS
US5233409A (en) 1992-02-25 1993-08-03 Schwab Karl W Color analysis of organic constituents in sedimentary rocks for thermal maturity
US5359115A (en) 1992-03-26 1994-10-25 Affymax Technologies, N.V. Methods for the synthesis of phosphonate esters
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
ES2204910T3 (en) 1992-10-01 2004-05-01 The Trustees Of Columbia University In The City Of New York COMPLEX COMBINATORY CHEMICAL LIBRARIES CODED WITH SIGNS.
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US5362899A (en) 1993-09-09 1994-11-08 Affymax Technologies, N.V. Chiral synthesis of alpha-aminophosponic acids
JPH11505704A (en) * 1995-05-17 1999-05-25 リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミネソタ Immunoconjugates Containing Single Chain Variable Region Fragments of Anti-CD-19 Antibodies
IT1395574B1 (en) 2009-09-14 2012-10-16 Guala Dispensing Spa DISTRIBUTION DEVICE

Also Published As

Publication number Publication date
EP1286682A1 (en) 2003-03-05
ES2343351T3 (en) 2010-07-29
CA2410458A1 (en) 2001-12-13
JP2004502412A (en) 2004-01-29
WO2001093892A1 (en) 2001-12-13
EP1286682A4 (en) 2004-10-13
EP2251026A1 (en) 2010-11-17
CN1443074A (en) 2003-09-17
DE60141463D1 (en) 2010-04-15
ATE459367T1 (en) 2010-03-15
EP1286682B1 (en) 2010-03-03

Similar Documents

Publication Publication Date Title
WO1994024187A3 (en) Organosilicon-containing materials useful for biomedical devices
PL346830A1 (en) 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors
TW278099B (en)
EP1170782A3 (en) Device for handling a disk-like workpiece
WO2000001850A3 (en) Molecular torches
WO1996017072A3 (en) Recombinant alphavirus vectors
WO1999054286A3 (en) Btk inhibitors and methods for their identification and use
DE60236622D1 (en) MOLD FOR OZONE-RESISTANT OBJECTS AND OZONE-RESISTANT INJECTION MATERIALS
WO1995007994A3 (en) Recombinant alphavirus vectors
ATE253063T1 (en) 5-HT1F AGONISTS
DE50200643D1 (en) Device and method for keeping food warm
EP0657942A3 (en) Lateral bipolar transistor.
AU2002307252A1 (en) System and method for protecting internet consumers and for certifying, identifying, segregating and locating traditional "brick and mortar" merchant businesses on the internet
AU693289B2 (en) Denatured low-density lipoprotein receptor
EP0616370A3 (en) Semiconductor bipolar device including SiGe and method for manufacturing the same.
EP1043353A4 (en) Method for modifying fluoropolymer
AU2001275378A1 (en) Methods and compositions for inhibiting immunoglobulin-mediated reperfusion inj ury
ZA977463B (en) Method for treating molded articles.
DE69828414D1 (en) MUCOSALE CYTOTOXIC T-LYMPHOCYTE RESPONSE
PL331882A1 (en) Substituted 1,2,3,4-tetrahydro-2-dibenzofurane amines and 2-amino cyclohepta[b]benzofuranes
TW276269B (en)
NZ511997A (en) Isonipecotamides for the treatment of integrin-mediated disorders
EA200301330A1 (en) INCREASED REMOVAL OF VOLATILE SUBSTANCES DURING SOLID-PHASE PROCESSING OF NAILON-6 THROUGH TEMPERATURE PROGRAMMING
GB9524590D0 (en) Method for tempering an injection molding tool,and injection molding tool for performing the method
NO950978D0 (en) Polyolefin-based pigmented blend, as well as process for making shaped articles based on blend